Emergent BioSolutions Inc.

EBS · NYSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$191-$761-$212$231
Dep. & Amort.$109$125$143$124
Deferred Tax-$6-$9-$29$47
Stock-Based Comp.$18$23$45$42
Change in WC$89-$70-$2-$156
Other Non-Cash$39$485$20$34
Operating Cash Flow$59-$206-$34$321
Investing Activities
PP&E Inv.-$23-$52-$116-$225
Net Acquisitions$0$270$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$148-$6-$266$0
Investing Cash Flow$125$212-$381-$225
Financing Activities
Debt Repay.-$198-$543$564-$36
Stock Issued$9$8$0$0
Stock Repurch.$0$0-$82-$106
Dividends Paid$0$0$0$0
Other Fin. Act.-$1-$1-$1$1
Financing Cash Flow-$190-$536$481-$141
Forex Effect$0-$1$1-$0
Net Chg. in Cash-$6-$531$66-$45
Supplemental Information
Beg. Cash$112$643$576$622
End Cash$106$112$643$576
Free Cash Flow$36-$258-$150$96